Skip to main content
Back to Variant Registry
PharmacogenomicsEvidence 2A

rs1801133 · MTHFR

Risk allele: A

Risk-Allele Phenotype

MTHFR rs1801133 — associated with altered drug response related to methotrexate — Chronic myelogenous leukemia, BCR-ABL1 positive;Graft vs Host Disease;Leukemia. This variant may influence medication efficacy or adverse reaction risk.

Reference-Allele Phenotype

Normal MTHFR function at this locus, with no elevated genetic risk contribution to methotrexate — Chronic myelogenous leukemia, BCR-ABL1 positive;Graft vs Host Disease;Leukemia from this variant.

Evidence Level

2AModerate — meta-analysis See methodology for how we grade evidence.

Cross-References

Informational only

This page summarizes population-level evidence about a genetic variant. It is not a diagnosis. Your individual risk depends on your full genome, lifestyle, environment, and family history. Consult a healthcare provider for personalized medical advice.

Want to know your status at rs1801133?

Upload your DNA file — Atlagene checks this variant as part of a 30,466-variant registry across 20 health categories.

Get Started Free
rs1801133 (MTHFR) — Pharmacogenomics | Atlagene